Ratings Masimo Corporation

Equities

MASI

US5747951003

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
136.1 ^USD	+0.67%		+1.02%	+16.15%

04-15	Stifel Upgrades Masimo to Buy From Hold, Raises Price Target to $170 From $148	MT
04-08	Apple to Allow Other Payment Options for Music Apps in Europe; Appeals to Overturn Apple Watch Import Ban	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.22 times its estimated earnings per share for the ongoing year.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
MASIMO CORPORATION	+16.15%	7.2B	C-
SHOCKWAVE MEDICAL, INC.	+73.17%	12.38B	B-
PENUMBRA, INC.	-18.74%	7.92B	C+
GETINGE AB	+6.46%	5.84B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.99%	5.07B	D+
APT MEDICAL INC.	+27.07%	4.53B	-
ASAHI INTECC CO., LTD.	-21.67%	3.88B	B-
INARI MEDICAL, INC.	-40.82%	2.23B	C
SKAN GROUP AG	+1.36%	2.02B	-
SHENZHEN YHLO BIOTECH CO., LTD.	+5.07%	1.88B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes